Market Research Logo

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023

Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company, the report provides:

  • Revenues
  • R&D Spending
  • Geographic Breakout of Revenues
  • Performance of Specific Products
  • Performance by Drug Category
  • Late-Stage Pipeline
  • Projections of Revenues to 2023
In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades.

The companies included in the study are:

Pfizer, inc.
Novartis AG
Roche ltd.
Merck & Co., inc.
Sanofi
Glaxosmithkline PLC
Johnson & johnson
Astra Zeneca plc
Eli Lilly and Company
Abbvie, inc.
Teva Pharmaceutical Industries, Ltd.
Amgen, inc.
Bristol-myers Squibb Company
Takeda Pharmaceutical co., LTD
Bayer AG
Novo nordisk
Boehringer Ingelheim gmbh
Daiichi Sankyo
Astellas
Gilead Sciences
Otsuka Pharmaceutical
Merck KGAA
Actavis
Mylan
Baxter international

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals; diagnostics; devices; chemicals; agriculture; and animal health. Strategic acquisitions and partnerships with biotech companies have allowed traditional pharmaceutical companies an opportunity to become diverse in pipelines and product offerings. Companies like Amgen, which specialize in biotechnology, now compete with a growing number of what the industry has once considered to be the traditional pharmaceutical company, This is a trend expected to continue to grow as interest in the small biotechnology focused companies continue to be acquired by the Pfizer's, Novartis' and Roche's of the industry


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • FUTURE MARKET OPPORTUNITY
      • Table Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023-based on late stage development projects evaluated ($ in billions)
    • LEADING COMPANIES
  • Introduction
    • GLOBAL PHARMACEUTICAL MARKET
    • TOP 25 PHARMACEUTICAL COMPANIES:AN OVERVIEW
      • Table Top Pharmaceutical Companies, 1-25 by 2013 Pharmaceutical Sales ($ millions)
    • GLOBAL HEALTHCARE SPENDING
      • Table Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2012
    • AGING POPULATION AND IMPACT ON PHARMACEUTICAL MARKETS
      • Table International Population Trend Age 65+ (Thousands)
      • Table United States Population Trend Age 65+ (Thousands)
  • Trends in Pharmaceutical Research and Development
    • PHARMACEUTICAL RESEARCH&DEVELOPMENT OVERVIEW
      • Percent of Approvals
      • Selecting Better Targets
        • Table Phases of Clinical Drug Development
      • Top R&D Spenders
        • Table Top R&D Spenders in the Pharmaceutical Industry 2011, 2012 and 2013 (in millions)
      • The Pipeline Snapshot
        • Table Company Pipelines by Total Late Stage Development Projects by General Therapeutic Segment (Top 25 Companies by Revenues)
    • EXPANDED OPTIONS IN TREATING DISEASES
    • BIOTECHNOLOGY DRUG DEVELOPMENT
    • ORPHAN DRUGS
      • Table Orphan Drug Designations Granted and Approved by the FDA 1983-2013
    • FAST TRACK DRUG STATUS
    • OTHERACCELERATED METHODS FOR DRUG APPROVAL
      • Breakthrough Therapy
    • PHARMACEUTICAL REGULATORY EXCLUSIVITY
      • Pediatric Extensions
    • PHARMACEUTICAL INDUSTRY-BIOSIMILAR (BIOGENERIC) DEVELOPMENT AND EXCLUSIVITY LEGISLATION
      • Complications with Biosimilar Development
      • U.S. Exclusivity for Biosimilars
      • Biosimilars in Japan and China
      • Biosimilars in Europe
    • CORPORATE STRATEGY:MERGERS,ACQUISITIONS, AND COLLABORATIONS
    • THE ROLE OF CONTRACT RESEARCH ORGANIZATIONS
  • Pfizer, Inc.
    • COMPANY OVERVIEW
      • Table Pfizer Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Pfizer: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
      • Geographic Market Participation
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Pfizer: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Pfizer: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Novartis AG
    • OVERVIEW
      • Table Novartis Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Novartis: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Novartis: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Novartis: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Roche Ltd.
    • OVERVIEW
      • Table Roche Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Roche: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Roche: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Roche: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Merck & Co., Inc.
    • OVERVIEW
      • Table Merck Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Merck: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Merck: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Merck: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Sanofi
    • OVERVIEW
      • Table Sanofi Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Sanofi: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Sanofi: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Sanofi Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • GlaxoSmithKline plc
    • OVERVIEW
      • Table GlaxoSmithKline Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table GlaxoSmithKline: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table GlaxoSmithKline: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table GlaxoSmithKline: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Johnson & Johnson
    • OVERVIEW
      • Table Johnson & Johnson Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Johnson & Johnson: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Johnson & Johnson: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Johnson & Johnson: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • AstraZeneca plc
    • OVERVIEW
      • Table AstraZeneca Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table AstraZeneca: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table AstraZeneca: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table AstraZeneca: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Eli Lilly and Company
    • OVERVIEW
      • Table Eli Lilly Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Eli Lilly's Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • Leading Products
      • Table Eli Lilly & Co.: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Eli Lilly: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • AbbVie, Inc.
    • OVERVIEW
      • Table AbbVie Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table AbbVie: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table AbbVie: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table AbbVie: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • TEVA Pharmaceutical Industries, Ltd.
    • OVERVIEW
      • Table Teva Pharmaceutical Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Teva Pharmaceutical: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Teva Pharmaceutical: Late Stage Product Pipeline Brand Development
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Amgen, Inc.
    • OVERVIEW
      • Table Amgen Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Amgen: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Amgen: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Amgen: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Bristol-Myers Squibb Company
    • OVERVIEW
      • Table Bristol-Myers Squibb Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Bristol-Myers Squibb's Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Bristol-Myers Squibb: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Bristol-Myers Squibb: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Takeda Pharmaceutical Co., Ltd.
    • OVERVIEW
      • Table Takeda Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Takeda's Total Company Revenue* and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Takeda: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Takeda Pharmaceutical: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Bayer AG
    • OVERVIEW
      • Table Bayer Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Bayer's Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Bayer: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Bayer: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Novo Nordisk
    • OVERVIEW
      • Table Novo Nordisk Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Novo Nordisk: Total Company Revenue and Total R&D Spending 2007-2013 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Novo Nordisk: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Novo Nordisk: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Boehringer Ingelheim GmbH
    • OVERVIEW
      • Table Boehringer Ingelheim Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Boehringer Ingelheim: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Boehringer Ingelheim: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Daiichi Sankyo
    • OVERVIEW
      • Table Daiichi Sankyo Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Daiichi Sankyo: Total Company Revenue and Total R&D Spending 2007-2013 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Daiichi Sankyo: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Daiichi Sankyo: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Astellas
    • OVERVIEW
      • Table Astellas Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Astellas: Total Company Revenue and Total R&D Spending 2007-2013 (millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Astellas: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Astellas: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Gilead Sciences
    • COMPANY OVERVIEW
      • Table Gilead Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Gilead Sciences: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Gilead Sciences: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Gilead Sciences: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Otsuka Pharmaceutical
    • COMPANY OVERVIEW
      • Table Otsuka Corporate Summary
    • FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Otsuka Holdings: Total Company Revenue and Total R&D Spending 2007-2013 (Thousands)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Otsuka Holdings: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Otsuka Holdings: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Merck KgaA
    • COMPANY OVERVIEW
      • Table Merck KGaA Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Merck KGaA: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
      • Leading Products
        • Table Merck KGaA: Leading Pharmaceutical Products, 2013 Sales (millions)
    • LATE STAGE PIPELINE
      • Table Merck KGaA: Late Stage Product Pipeline
    • GROWTH STRATEGY
      • Table Corporate Development Details
  • Actavis
    • COMPANY OVERVIEW
      • Table Actavis Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Actavis: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • LATE STAGE PIPELINE
      • Table Actavis: Late Stage Product Pipeline Brand Development
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Mylan
    • COMPANY OVERVIEW
      • Table Mylan Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Mylan: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • PIPELINE
    • GROWTH STRATEGY
      • Table Corporate Development Details
  • Baxter International
    • COMPANY OVERVIEW
      • Table Baxter Corporate Summary
    • COMPANY FINANCIAL PERFORMANCE AND INVESTMENTS
      • Table Baxter: Total Company Revenue and Total R&D Spending 2007-2013 (Millions)
    • GEOGRAPHIC MARKET PARTICIPATION
    • PHARMACEUTICAL BUSINESS PERFORMANCE
    • PIPELINE
    • GROWTH STRATEGY
      • Table Highlighted Corporate Developments
  • Market Summary and Forecast Analysis
    • OVERVIEW
      • Table Global Pharmaceutical Market, 2011-2013 and Forecasted 2023 ($ in billions)
    • MARKET TRENDS AND VALUES BY THERAPEUTICAREA
      • Cardiovascular/Blood Market Analysis
      • Neurotherapeutics Market Analysis
      • Infection Treatments Market Analysis
      • Oncology Market Analysis
      • Respiratory and Inflammation Market Analysis
      • Other Drug Market Analysis
    • EVALUATING CHANGES IN 2013MARKET VALUE
      • Year-over-Year Growth Analysis
        • Table Top Companies by 2013 Pharmaceutical Sales Growth (millions)
    • COMPANY ANALYSIS
      • Table Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013 Compared to 2011 (millions)
      • Table Top 25 Pharmaceutical Products, by 2011 and 2013 Revenues (billions)
    • MARKET FORECAST
      • Table Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023-based on late stage development projects evaluated ($ in billions)
    • FUTURE COMPANY OUTLOOK
      • Table Evaluating Pharmaceutical Company Growth, 2013-2023 ($ millions)
      • Sustainability in a Changing Pharmaceutical Industry
    • CONCLUSIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report